Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1961 1
1962 1
1963 1
1964 1
1965 3
1966 1
1967 2
1968 2
1969 4
1970 1
1971 4
1972 5
1973 4
1974 4
1975 6
1976 4
1977 7
1978 1
1979 7
1980 6
1981 5
1982 4
1983 5
1984 4
1986 1
1987 4
1988 4
1989 13
1990 7
1991 2
1993 2
1994 4
1995 2
1996 6
1997 2
1998 5
1999 6
2000 11
2001 9
2002 8
2003 11
2004 24
2005 20
2006 12
2007 7
2008 15
2009 14
2010 24
2011 21
2012 32
2013 32
2014 18
2015 38
2016 31
2017 37
2018 42
2019 43
2020 38
2021 52
2022 48
2023 48
2024 40
2025 29

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

748 results

Results by year

Filters applied: . Clear all
Page 1
An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping.
Kawasaki K, Toshimitsu K, Matano M, Fujita M, Fujii M, Togasaki K, Ebisudani T, Shimokawa M, Takano A, Takahashi S, Ohta Y, Nanki K, Igarashi R, Ishimaru K, Ishida H, Sukawa Y, Sugimoto S, Saito Y, Maejima K, Sasagawa S, Lee H, Kim HG, Ha K, Hamamoto J, Fukunaga K, Maekawa A, Tanabe M, Ishihara S, Hamamoto Y, Yasuda H, Sekine S, Kudo A, Kitagawa Y, Kanai T, Nakagawa H, Sato T. Kawasaki K, et al. Among authors: hamamoto y. Cell. 2020 Nov 25;183(5):1420-1435.e21. doi: 10.1016/j.cell.2020.10.023. Epub 2020 Nov 6. Cell. 2020. PMID: 33159857 Free article.
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Kang YK, et al. Among authors: hamamoto y. Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6. Lancet. 2017. PMID: 28993052 Clinical Trial.
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y. Kato K, et al. Among authors: hamamoto y. Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30. Lancet Oncol. 2019. PMID: 31582355 Clinical Trial.
[Tourette Syndrome].
Hamamoto Y, Kano Y. Hamamoto Y, et al. Brain Nerve. 2018 Nov;70(11):1237-1245. doi: 10.11477/mf.1416201169. Brain Nerve. 2018. PMID: 30416117 Japanese.
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
Yamada Y, Katagiri H, Hamamoto Y, Deenadayalan S, Navarria A, Nishijima K, Seino Y; PIONEER 9 investigators. Yamada Y, et al. Among authors: hamamoto y. Lancet Diabetes Endocrinol. 2020 May;8(5):377-391. doi: 10.1016/S2213-8587(20)30075-9. Lancet Diabetes Endocrinol. 2020. PMID: 32333875 Clinical Trial.
Author's reply.
Hamamoto Y, Tokushige A, Yuasa T, Ikeda Y, Horizoe Y, Yasuda H, Kubozono T, Ohishi M. Hamamoto Y, et al. J Cardiol. 2023 Jan;81(1):117-118. doi: 10.1016/j.jjcc.2022.07.012. Epub 2022 Sep 13. J Cardiol. 2023. PMID: 36109258 Free article. No abstract available.
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.
Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima H, Kang YK, Boku N. Chen LT, et al. Among authors: hamamoto y. Gastric Cancer. 2020 May;23(3):510-519. doi: 10.1007/s10120-019-01034-7. Epub 2019 Dec 20. Gastric Cancer. 2020. PMID: 31863227 Free PMC article. Clinical Trial.
Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial.
Kogure Y, Iwasawa S, Saka H, Hamamoto Y, Kada A, Hashimoto H, Atagi S, Takiguchi Y, Ebi N, Inoue A, Kurata T, Okamoto I, Yamaguchi M, Harada T, Seike M, Ando M, Saito AM, Kubota K, Takenoyama M, Seto T, Yamamoto N, Gemma A. Kogure Y, et al. Among authors: hamamoto y. Lancet Healthy Longev. 2021 Dec;2(12):e791-e800. doi: 10.1016/S2666-7568(21)00255-5. Lancet Healthy Longev. 2021. PMID: 36098037 Free article. Clinical Trial.
748 results